---
title: "PTNT.US (PTNT.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PTNT.US/news.md"
symbol: "PTNT.US"
name: "PTNT.US"
parent: "https://longbridge.com/en/quote/PTNT.US.md"
datetime: "2026-03-06T14:08:48.917Z"
locales:
  - [en](https://longbridge.com/en/quote/PTNT.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PTNT.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PTNT.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/PTNT.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/PTNT.US/news.md)


# PTNT.US (PTNT.US) — Related News

### [Palamina Corp. Grants 4 Million Stock Options to Management and Advisors](https://longbridge.com/en/news/273157639.md)
*2026-01-21T01:51:35.000Z*
> Palamina Corp. has granted 4,025,000 stock options to its management and advisors under its Stock Option Plan, exercisab

### [Palatin Technologies, Inc. | 10-K: FY2025 Revenue: USD 0](https://longbridge.com/en/news/258588097.md)
*2025-09-23T21:02:08.000Z*
### [Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 | PTN Stock News](https://longbridge.com/en/news/239555182.md)
*2025-05-09T11:30:00.000Z*
> Palatin Technologies, Inc. presented promising preclinical data on its melanocortin agonists PL9654 and PL9655 for treat

### [Palatin Technologies closes public offering, transitions to OTC Pink (PTNT) on May 8, 2025.](https://longbridge.com/en/news/239466584.md)
*2025-05-09T02:42:08.000Z*
> In a move that took place on May 8, 2025, a company headquartered in Cranbury, New Jersey, Palatin Technologies, Inc., o

### [Palatin Technologies Announces Closing of Reduced Public Offering | PTN Stock News](https://longbridge.com/en/news/239464278.md)
*2025-05-09T02:19:00.000Z*
> Palatin Technologies, Inc. has announced the closing of a reduced public offering, raising approximately $1.1 million th

### [Palatin unveils promising Phase 3 results of PL9643 for dry eye disease at ARVO 2025, with 6 of 13 symptoms resolved.](https://longbridge.com/en/news/239427621.md)
*2025-05-08T21:02:45.000Z*
> In the latest Phase 3 analysis, PL9643 has emerged as a promising first-of-its-kind treatment with the potential for com

### [Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 | PTN Stock News](https://longbridge.com/en/news/239424906.md)
*2025-05-08T20:39:00.000Z*
> Palatin Technologies presented promising Phase 3 data for PL9643, a potential first-in-class treatment for dry eye disea

### [Palatin Technologies Announces Upcoming Clinical Trials for Next-Gen Obesity Treatments and Ocular Collaborations Set for 2025](https://longbridge.com/en/news/239124943.md)
*2025-05-07T12:15:29.000Z*
> Palatin Technologies Inc. announced plans to advance its obesity program with next-generation MC4R long-acting peptides 

### [Palatin Technologies Launches $23 Million Public Offering, Including $11.5 Million Upfront and Potential Additional $11.5 Million from Warrant Exercises](https://longbridge.com/en/news/239122040.md)
*2025-05-07T12:04:38.000Z*
> Palatin Technologies Inc. has launched a public offering of 76,666,667 shares of common stock and Series F warrants, aim